Johnson Matthey has leading capabilities in developing optimal polymorphs, salt forms, crystal morphology and controlled particles through our PHARMORPHIX® solid form sciences. We offer one of the broadest and most reliable services to ensure effective identification, development and manufacture of your drug candidates and commercial products.

Watch our webinar: Understanding solid form and crystallisation presented by Dr Thomas Kendall

Download our solid state services flyer


download webinar question and answers session

Download flyer


Our solid form services include:


Polymorph screening

Polymorph Screening is the identification and characterisation of all relevant polymorphic forms of a pharmaceutical compound.  Many pharmaceutical compounds are able to form two or more crystalline phases, this is known as polymorphism. It is important that the polymorphs of a compound are assessed, as different polymorphs have different physicochemical properties that may have an impact on the intended use of the material. The selection of a specific crystal form of an API early in drug discovery mitigate the chances of risk in the later stages of development.

Salt screening

Salt screening is a crucial step in modern drug development, as the presence of various salt forms can increase the dissolution rate and oral bioavailability of an API. By identifying and assessing various salt forms of a drug substance, drug developers are able to select an optimal counterion early in the lifecycle and reduce the chance of risk later in drug development.

Co-crystal development   

Co-crystal Development is an increasingly popular step in the drug development process. By forming co-crystals – crystalline complexes formed by two (or more) separate molecular entities – drug developers can modify the physical properties of an API while preserving the benefits of a crystalline solid form.

Amorphous dispersion 

Amorphous Dispersion is a strategy used to improve the solubility and oral bioavailability of poorly water-soluble pharmaceutical compounds. In these systems an amorphous active pharmaceutical ingredient (API) is stabilised by a polymer to produce an arrangement with improved physical and solution stability.


Crystallography is the detailed analysis of crystal structures. By using powerful methods - such as X-ray crystallography - drug developers can assign the of absolute stereochemistry of chiral centres and determine the structure from the smallest of crystals.

Physical and chemical analysis 

Physical and Chemical Analysis is the process used to assess the performance of novel crystalline forms, design-appropriate salt and co-crystal screens and investigate alternative drug delivery routes. Our physchem data package provides comprehensive physicochemical characterisation for your compound using specialist instruments and software, to provide the maximum amount of high-quality information, when only limited material is available. 

Chiral separations 

Chiral Separations is a process used to separate a racemic mixture of two isomers into their constituent enantiomers. Although enantiomers have the identical physical properties, the varying isomers exhibit marked differences in biological activities such as pharmacology and toxicology. Therefore, various methodologies have been formed for chiral separation on both analytical and preparative scales.

Crystallisation development

Crystallisation development is an essential step utilised throughout the production of pharmaceutical drugs. Crystallisation provides a separation process for intermediates and is applied as the final step in the manufacture of active pharmaceutical ingredients (APIs).

Get in touch

Send us a message to request a quote or ask our advice. We'd be happy to hear from you.

Liz Edmond

    Send a message

    Read more


    Read about our custom pharma solutions

    Custom pharmaceutical solutions Custom pharmaceutical solutions


    Read our PHARMORPHIX® flyer